AC6 Stock Chart & Stats
€0.15
>-€0.01(-7.07%)
At close: 4:00 PM EST
€0.15
>-€0.01(-7.07%)
Day’s Range― - ―
52-Week Range€0.07 - €0.74
Previous CloseN/A
Volume0.00
Average Volume (3M)114.00
Market Cap
€95.73M
Enterprise Value€453.76M
Total Cash (Recent Filing)€32.97M
Total Debt (Recent Filing)€2.29M
Price to Earnings (P/E)―
Beta-0.49
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding137,897,340
10 Day Avg. Volume0
30 Day Avg. Volume114
Financial Highlights & Ratios
PEG Ratio-1.96
Price to Book (P/B)6.11
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Partnering / Licensing Business ModelA clear partnering/licensing model is durable for a small biotech: it allows the company to focus capital on discovery while creating non-dilutive or milestone-driven value events. Over months this reduces need for commercial capabilities and increases optionality to monetize programs via partners or deals.
Focused CNS Pipeline & Discovery PlatformsA concentrated CNS focus (Alzheimer’s, pain) and in-house discovery platforms provide structural advantages: domain expertise increases technical credibility with partners, and a platform can seed multiple candidates, improving odds of at least one program reaching partnering milestones over the medium term.
Relatively Low Financial LeverageLow debt levels reduce fixed obligations and bankruptcy risk for a cash-burning R&D firm. Structurally, limited leverage preserves flexibility to negotiate partnerships or time financing rounds, and lowers the chance of debt-driven distress during multi-quarter development cycles.
Bears Say
Zero Revenue; Persistent Large LossesNo commercial revenue combined with sustained, large operating losses means the company must rely on external funding or partner deals to continue. Over the medium term this limits self-funding of trials, forces prioritization of programs, and heightens execution risk if capital access tightens.
High And Worsening Cash BurnSubstantial negative operating and free cash flow is a structural vulnerability: it shortens runway, increases probability of dilutive equity raises or deal-driven financings, and constrains the ability to progress multiple programs concurrently without sacrificing strategic optionality.
Shrinking Equity Base And Financing DependenceA rapidly declining equity base signals capital erosion from cumulative losses and prior financing; structurally this raises the likelihood of further dilution, reduces the buffer to absorb setbacks, and makes future funding rounds more impactful on ownership and strategy execution.
AC6 FAQ
What was AlzeCure Pharma AB’s price range in the past 12 months?
AlzeCure Pharma AB lowest stock price was €0.07 and its highest was €0.74 in the past 12 months.
What is AlzeCure Pharma AB’s market cap?
AlzeCure Pharma AB’s market cap is €95.73M.
When is AlzeCure Pharma AB’s upcoming earnings report date?
AlzeCure Pharma AB’s upcoming earnings report date is Aug 26, 2026 which is in 51 days.
How were AlzeCure Pharma AB’s earnings last quarter?
AlzeCure Pharma AB released its earnings results on May 05, 2026. The company reported -€0.015 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.015.
Is AlzeCure Pharma AB overvalued?
According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued.
Does AlzeCure Pharma AB pay dividends?
AlzeCure Pharma AB does not currently pay dividends.
What is AlzeCure Pharma AB’s EPS estimate?
AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AlzeCure Pharma AB have?
AlzeCure Pharma AB has 137,897,340 shares outstanding.
What happened to AlzeCure Pharma AB’s price movement after its last earnings report?
AlzeCure Pharma AB reported an EPS of -€0.015 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.024%.
Which hedge fund is a major shareholder of AlzeCure Pharma AB?
Currently, no hedge funds are holding shares in DE:AC6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AlzeCure Pharma AB
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. The company was founded in 2012 and is based in Huddinge, Sweden.